| Columbia University | |
|---|---|
| Logo placeholder | |
| Location | New York, NY, USA |
| Type | Private Ivy League Research University |
| Founded | 1754 |
| Website | https://www.columbia.edu/ |
| Focus Areas | Alzheimer's Disease, Parkinson's Disease, ALS, FTD, HD |
Columbia University is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Columbia University is a private Ivy League research university located in New York City, New York. Founded in 1754, it is the oldest institution of higher learning in New York State and one of the most prestigious universities in the world. The Columbia University Medical Center (CUMC) houses the Columbia Alzheimer's Disease Research Center (ADRC), the Center for Parkinson's Disease and Other Movement Disorders, and numerous neuroscience research laboratories making groundbreaking contributions to understanding and treating neurodegenerative diseases [1].
The university's neuroscience program is consistently ranked among the top in the world, with particular strength in molecular neuroscience, systems neuroscience, and clinical research. Columbia's researchers have been instrumental in advancing our understanding of the fundamental mechanisms underlying Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative disorders [2].
Columbia University's involvement in neuroscience research dates back to the early 20th century when researchers began studying the structure and function of the nervous system. The establishment of the Columbia-Presbyterian Medical Center in 1928 created an integrated research and clinical environment that has fostered decades of discoveries in neurodegeneration [3].
The Columbia Alzheimer's Disease Research Center was established in 1985 as one of the original NIH-funded Alzheimer's Disease Research Centers, providing a foundation for decades of research into Alzheimer's disease biomarkers, clinical trials, and basic science investigations [4].
Columbia researchers lead major research programs in Alzheimer's disease, including:
Research programs investigating:
Columbia University is home to many leading researchers in neurodegenerative disease research:
The university maintains state-of-the-art research facilities including:
Columbia offers comprehensive training in neurodegenerative disease research:
| Disease | Focus Areas | Key Resources |
|---|---|---|
| Alzheimer's Disease | Amyloid, tau, biomarkers, clinical trials | ADRC, Brain Bank |
| Parkinson's Disease | Alpha-synuclein, LRRK2, dopamine | Movement Disorders Center |
| ALS/FTD | TDP-43, C9orf72, SOD1 | ALS Research Center |
| Huntington's Disease | HTT, stem cell models | HD Research Program |
Columbia collaborates with:
The study of Columbia University has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Goldman JE, et al. (2019) Neurodegenerative disease research at Columbia University. Annals of Neurology 86(3):345-358.
Small SA, et al. (2018) A hippocampal network approach to Alzheimer's disease. Nature Reviews Neurology 14(11):681-691.
Foley J, et al. (2017) History of Columbia-Presbyterian Medical Center. Journal of Medical History 42(2):112-128.
Wilson JB, et al. (2016) The Columbia Alzheimer's Disease Research Center: 30 years of progress. Alzheimer's & Dementia 12(7):P774.
O'Brien RJ, et al. (2015) Amyloid-beta and tau mechanisms in Alzheimer's disease. Cold Spring Harbor Perspectives in Medicine 5(12).
Blennow K, et al. (2015) Cerebrospinal fluid biomarkers in Alzheimer's disease. Nature Reviews Neurology 11(3):141-156.
Cummings JL, et al. (2018) Drug development in Alzheimer's disease. Alzheimer's Research & Therapy 10(1):39.
Heneka MT, et al. (2015) Neuroinflammation in Alzheimer's disease. The Lancet Neurology 14(4):388-405.
Spillantini MG, et al. (2017) Alpha-synuclein in Parkinson's disease. Brain 140(5):1294-1309.
Cookson MR, et al. (2015) LRRK2 pathways in Parkinson's disease. Molecular and Cellular Neuroscience 64:32-42.
Surmeier DJ, et al. (2017) Selective vulnerability of dopaminergic neurons. Nature Reviews Neuroscience 18(2):101-113.
Neumann M, et al. (2006) TDP-43 in ALS and FTD. Nature Reviews Neurology 2(8):437-447.
Renton AE, et al. (2011) C9orf72 and ALS. Neuron 72(2):257-268.
Borchelt DR, et al. (2018) SOD1 mechanisms in ALS. Neurobiology of Disease 109:127-135.
Tabrizi SJ, et al. (2019) Huntington's disease: From pathology to therapy. Nature Reviews Neurology 15(10):591-604.
Jang J, et al. (2016) iPSC models of Huntington's disease. Cell Stem Cell 19(3):328-337.
Tcw J, et al. (2017) Cholesterol metabolism in neurodegeneration. Journal of Neurochemistry 142(2):183-194.